Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2012 May;23(5):1138-1144.
doi: 10.1093/annonc/mdr438. Epub 2011 Oct 10.

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

B Ejlertsen  1 , J Aldridge  2 , K V Nielsen  3 , M M Regan  4 , K L Henriksen  5 , A E Lykkesfeldt  5 , S Müller  3 , R D Gelber  6 , K N Price  7 , B B Rasmussen  8 , G Viale  9 , H Mouridsen  10 ; Danish Breast Cancer Cooperative Group the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group
Affiliations
Multicenter Study

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

B Ejlertsen et al. Ann Oncol. 2012 May.

Abstract

Background: Estrogen Receptor 1 (ESR1) aberrations may be associated with expression of estrogen receptor (ER) or progesterone receptor (PgR), human epidermal growth factor receptor-2 (HER2) or Ki-67 labeling index and prognosis.

Patients and methods: ESR1 was assessed in 1129 (81%) of 1396 postmenopausal Danish women with early breast cancer randomly assigned to receive 5 years of letrozole, tamoxifen or a sequence of these agents in the Breast International Group 1-98 trial and who had ER ≥ 1% after central review.

Results: By FISH, 13.6% of patients had an ESR1-to-Centromere-6 (CEN-6) ratio ≥ 2 (amplified), and 4.2% had ESR1-to-CEN-6 ratio <0.8 (deleted). Deletion of ESR1 was associated with significantly lower levels of ER (P < 0.0001) and PgR (P = 0.02) and more frequent HER2 amplification. ESR1 deletion or amplification was associated with higher-Ki-67 than ESR1-normal tumors. Overall, there was no evidence of heterogeneity of disease-free survival (DFS) or in treatment effect according to ESR1 status. However, significant differences in DFS were observed for subsets based on a combination of ESR1 and HER2 status (P = 0.02).

Conclusions: ESR1 aberrations were associated with HER2 status, Ki-67 labeling index and ER and PgR levels. When combined with HER2, ESR1 may be prognostic but should not be used for endocrine treatment selection in postmenopausal women with endocrine-responsive early breast cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Box plots illustrating the distribution of ER, PgR and Ki-67 labeling index expression levels according to ESR1 status. Boxes indicate 25th, 50th (median) and 75th percentiles. P values were derived from Wilcoxon rank-sum test for ER percent (P < 0.0001), PgR percent (P = 0.02) and Ki-67 labeling index percent (P < 0.0001) and from Fisher’s exact tests for HER2 (P = 0.04). Missing values were omitted. ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor-2.
Figure 2.
Figure 2.
Kaplan–Meier estimates of disease-free survival according to ESR1 status (A) and according to ESR1 status and HER2 status categories (B). HER2, human epidermal growth factor receptor-2.
Figure 3.
Figure 3.
Cox proportional hazards model for disease-free survival comparing ESR1-deleted and ESR1-amplified cohorts (aberrant cohorts) versus the ESR1-normal cohort overall and for subgroups defined by HER2 status and Ki-67 labeling index category. Hazard ratio values <1.0 indicate a better outcome for the aberrant (either deleted or amplified) compared with ESR1 normal. HER2, human epidermal growth factor receptor-2.
See this image and copyright information in PMC

References

    1. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. - PubMed
    1. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319–1329. - PMC - PubMed
    1. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795. - PMC - PubMed
    1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. - PubMed
    1. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer. 2007;7(7):545–553. - PubMed

Publication types

MeSH terms